![Roberto Iacone](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Dr. Roberto Iacone is a Chief Executive Officer & Director at Alentis Therapeutics AG and a Venture Partner at Pureos Partners AG.
He is on the Board of Directors at Alentis Therapeutics AG.
Dr. Iacone was previously employed as a Co-Founder by Bright Peak Therapeutics AG and a Co-Founder by Ridgeline Therapeutics.
He received his doctorate degree from Università degli Studi di Napoli Federico II.
| Unternehmen | Position | Beginn |
|---|---|---|
Pureos Partners AG
 Pureos Partners AG Investment ManagersFinance Pureos Partners invests in companies located in Switzerland. The firm focuses on drug development companies. It participates in early stage capital transactions. | Private Equity Investor | - |
| Unternehmen | Position | Ende |
|---|---|---|
Alentis Therapeutics AG
 Alentis Therapeutics AG BiotechnologyHealth Technology Operates as a clinical-stage biotech company that develops therapies to treat cancer and reverse fibrosis | Vorstandsvorsitzender | 15.10.2025 |
Ridgeline Therapeutics | Gründer | - |
Bright Peak Therapeutics AG
 Bright Peak Therapeutics AG BiotechnologyHealth Technology Develops immuno-oncology therapeutics | Head-Fixed Income Invts | - |
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
| Private Unternehmen | 5 |
|---|---|
Università degli Studi di Napoli Federico II
 Università degli Studi di Napoli Federico II Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Pureos Partners AG
Pureos Partners AG Investment ManagersFinance Pureos Partners invests in companies located in Switzerland. The firm focuses on drug development companies. It participates in early stage capital transactions. | Finance |
Alentis Therapeutics AG
Alentis Therapeutics AG BiotechnologyHealth Technology Operates as a clinical-stage biotech company that develops therapies to treat cancer and reverse fibrosis | Health Technology |
Bright Peak Therapeutics AG
Bright Peak Therapeutics AG BiotechnologyHealth Technology Develops immuno-oncology therapeutics | Health Technology |
Ridgeline Therapeutics |
Bitte wählen Sie Ihre Ausgabe
Alle länderspezifischen Finanzinformationen
